8 research outputs found
Π Π°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ»Π΅ΠΊΡΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ Π³Π΅Π½Π΅Π·Π°
Background.At the same time, the main effect of the use of this drug is the elimination of the autonomic nervous system dysfunction and sympatholysis. It seems important to search for a method of indications and selection of a dose of dexmedetomidine in intensive care.Aims to improve the clinical effectiveness of the electrophysiological navigation of the prolonged use of dexmedetomidine in patients with brain pathology of various origins.Methods.The study included 83 patients 2050 days after the traumatic brain injury, anoxic damage; consequences of acute disorders of cerebral. 37 patients comprised the 1st intervention group with a clinical course of dexmedetomidine (male 28; female 9; average age 49.62.3 years) and 46 patients comprised the 2nd control group without pharmacological correction with dexmedetomidine (male 23; female 23, average age 512.5 years). Criteria for the inclusion of prolonged infusion of the drug dexmedetomidine (Orion Pharma, Finland) are based on heart rate variability (HRV) indicators characteristic of sympathetic hyperactivity, the target task of titration of doses of dexmedetomidine served as the parameters for achieving normal HRV indicators, the appearance of parasympathetic hyperactivity served as the basis for reducing the dosage of the drug or stopping it of application. HRV parameters were recorded before dexmetomedine infusion-initially, on 13; 45; 910; 1520 days of drug administration.Results.The starting dose of dexmedetomidine with sympathetic hyperactivity in patients was 0.12 to 0.24 g.kg1.hr1(average dose 0.160.01; total 200 mg/day). According to digital data from HRV, the effective dose of dexmedetomidine ED50 was 0.260.03 g.kg1.hr1(total daily 353.835.1 g) and was achieved on day 910 using dexmedetomidine.Conclusions.The protective role of dexmedetomidine with correction of sympathetic hyperactivity based on electrophysiological navigation according to the HRV is reliable in the following indicators: The improvement of consciousness; a significant decrease in the incidence of distress lung syndrome; septic shock; mortality.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. ΠΠ΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΡΡΡΠΏΡΠΈΠΏΡΠΎΡΠ΅Π΄ΡΡΠ½ΠΎΠΉ ΡΠ΅Π΄Π°ΡΠΈΠΈΠΈΠ»ΠΈΠΊΠ²ΠΈΠ΄Π°ΡΠΈΠΈ ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΡΠΈΠΌΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΠ°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ (Π°ΠΆΠΈΠΎΡΠ°ΡΠΈΡ, ΡΠ°Ρ
ΠΈΠΊΠ°ΡΠ΄ΠΈΡ, Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΡΠΈΡ.ΠΏ.). ΠΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠΈ Π°Π²ΡΠΎΠ½ΠΎΠΌΠ½ΠΎΠΉ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡΠΈΡΠΈΠΌΠΏΠ°ΡΠΎΠ»ΠΈΠ·ΠΈΡ. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡΡΡ Π²Π°ΠΆΠ½ΡΠΌΠΈ ΠΏΠΎΠΈΡΠΊ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΎΠ±ΡΠ΅ΠΊΡΠΈΠ²ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉΠΈΠΏΠΎΠ΄Π±ΠΎΡ Π΄ΠΎΠ·Ρ Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π°Π²ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ»ΡΡΡΠΈΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π°ΠΈΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡΠΈΠ΄ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π°ΡΠΏΠΎΠΌΠΎΡΡΡ ΡΠ»Π΅ΠΊΡΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π°Π²ΠΈΠ³Π°ΡΠΈΠΈΡΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²ΡΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ Π³Π΅Π½Π΅Π·Π°.ΠΠ΅ΡΠΎΠ΄Ρ.ΠΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 83 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° (51 ΠΌΡΠΆΡΠΈΠ½Π°, 32 ΠΆΠ΅Π½ΡΠΈΠ½Ρ; ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 50,381,7 Π³ΠΎΠ΄Π°)Π²ΠΏΠ΅ΡΠΈΠΎΠ΄ Π±ΠΎΠ»Π΅Π΅ 20Π΄Π½Π΅ΠΉΡΠΏΠΎΡΠ»Π΅Π΄ΡΡΠ²ΠΈΡΠΌΠΈ: ΡΠ΅ΡΠ΅ΠΏΠ½ΠΎ-ΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠΉ ΡΡΠ°Π²ΠΌΡ (Π§ΠΠ’) (n=24; 28,9%); ΠΎΡΡΡΠΎΠ³ΠΎ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ (ΠΠΠΠ) (n=17; 20,5%); Π°Π½ΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° (n=16; 19,3%); ΡΡΠ±Π°ΡΠ°Ρ
Π½ΠΎΠΈΠ΄Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΈΠ·Π»ΠΈΡΠ½ΠΈΡ (n=23; 27,7%); Π½Π΅ΠΉΡΠΎΡ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΉΠ½Π°Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅ (n=3; 3,6%). 37 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (28 ΠΌΡΠΆΡΠΈΠ½, 9 ΠΆΠ΅Π½ΡΠΈΠ½; ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 49,62,3 Π³ΠΎΠ΄Π°) ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ ΠΏΠ΅ΡΠ²ΡΡ Π³ΡΡΠΏΠΏΡ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Π°cΠΊΡΡΡΠΎΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π°ΠΈ46 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (23 ΠΌΡΠΆΡΠΈΠ½Ρ, 23 ΠΆΠ΅Π½ΡΠΈΠ½Ρ; ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 512,5 Π³ΠΎΠ΄Π°) Π²ΡΠΎΡΡΡ (ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ) Π³ΡΡΠΏΠΏΡΠ±Π΅Π·ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½ΠΎΠΌ. ΠΡΠΈΡΠ΅ΡΠΈΠΈ Π½Π°ΡΠ°Π»Π° ΠΏΡΠΎΠ»ΠΎΠ½Π³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΈΠ½ΡΡΠ·ΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π° (ΡΠΈΡΠΌΠ°OrionPharma, Π€ΠΈΠ½Π»ΡΠ½Π΄ΠΈΡ) ΠΎΡΠ½ΠΎΠ²Π°Π½ΡΠ½Π°ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΡ
Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΠΈ ΡΠΈΡΠΌΠ° ΡΠ΅ΡΠ΄ΡΠ° (ΠΠ Π‘), Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΡ
Π΄Π»ΡΡΠΈΠΌΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ; ΡΠ°ΡΠ³Π΅ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π·Π°Π΄Π°ΡΠ΅ΠΉ ΡΠΈΡΡΠΎΠ²Π°Π½ΠΈΡ Π΄ΠΎΠ·Ρ Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π° ΡΠ»ΡΠΆΠΈΠ»ΠΈ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ Π½ΠΎΡΠΌΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΠ Π‘; ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΠ΅ ΠΏΠ°ΡΠ°ΡΠΈΠΌΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΠ°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ»ΡΠΆΠΈΠ»ΠΎ ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΡ Π΄ΠΎΠ·ΠΈΡΠΎΠ²ΠΊΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΈΠ»ΠΈΠΏΡΠ΅ΠΊΡΠ°ΡΠ΅Π½ΠΈΡ Π΅Π³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ (ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈΡΡ 5-ΠΌΠΈΠ½ΡΡΠ½ΡΠ΅ Π·Π°ΠΏΠΈΡΠΈ ΠΊΠ°ΡΠ΄ΠΈΠΎΠΈΠ½ΡΠ΅ΡΠ²Π°Π»ΠΎΠ² (ΠΏΡΠΈΠ±ΠΎΡ ΠΠΎΠ»ΠΈΡΠΏΠ΅ΠΊΡΡ-8 ΠΠ₯ ΡΠΈΡΠΌΡ ΠΠ΅ΠΉΡΠΎΡΠΎΡΡ, Π ΠΎΡΡΠΈΡ)). Π Π΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π»ΠΈ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΠ Π‘: SI ΡΡΡΠ΅ΡΡ-ΠΈΠ½Π΄Π΅ΠΊΡ ΠΠ°Π΅Π²ΡΠΊΠΎΠ³ΠΎ (ΠΈΠ½Π΄Π΅ΠΊΡ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΡ ΡΠ΅Π³ΡΠ»ΡΡΠΎΡΠ½ΡΡ
ΡΠΈΡΡΠ΅ΠΌ ΠΈΠ½Π΄Π΅ΠΊΡ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΡ)Π²Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΡ
Π΅Π΄ΠΈΠ½ΠΈΡΠ°Ρ
(Π½.Π΅.); SDNN ΡΡΠ΅Π΄Π½Π΅ΠΊΠ²Π°Π΄ΡΠ°ΡΠΈΡΠ½ΠΎΠ΅ ΠΎΡΠΊΠ»ΠΎΠ½Π΅Π½ΠΈΠ΅ RR-ΠΊΠ°ΡΠ΄ΠΈΠΎΠΈΠ½ΡΠ΅ΡΠ²Π°Π»ΠΎΠ²Π²ΠΌΡ; rMSSD ΡΡΠ΅Π΄Π½Π΅ΠΊΠ²Π°Π΄ΡΠ°ΡΠΈΡΠ½ΠΎΠ΅ ΠΎΡΠΊΠ»ΠΎΠ½Π΅Π½ΠΈΠ΅ ΡΠ°Π·Π½ΠΎΡΡΠΈ Π΄Π²ΡΡ
ΡΠΌΠ΅ΠΆΠ½ΡΡ
ΠΎΡΡΡΠ΅ΡΠΎΠ² RR-ΠΊΠ°ΡΠ΄ΠΈΠΎΠΈΠ½ΡΠ΅ΡΠ²Π°Π»ΠΎΠ²Π²ΠΌΡ; pNN50% Π΄ΠΎΠ»Ρ RR-ΠΊΠ°ΡΠ΄ΠΈΠΎΠΈΠ½ΡΠ΅ΡΠ²Π°Π»ΠΎΠ²Π²ΠΏΡΠΎΡΠ΅Π½ΡΠ°Ρ
, ΠΎΡΠ»ΠΈΡΠ°ΡΡΠΈΡ
ΡΡΠΎΡΠΏΡΠ΅Π΄ΡΠ΄ΡΡΠ΅Π³ΠΎ Π±ΠΎΠ»Π΅Π΅ ΡΠ΅ΠΌΠ½Π°50 ΠΌΡ;TP ΠΎΠ±ΡΠ°Ρ ΠΌΠΎΡΠ½ΠΎΡΡΡ ΡΠΏΠ΅ΠΊΡΡΠ° ΡΠ°ΡΡΠΎΡΠ²ΠΌΡΠ΅ΠΊ2. ΠΠ°ΡΠ°ΠΌΠ΅ΡΡΡ ΠΠ Π‘ ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π»ΠΈΠ΄ΠΎΠΈΠ½ΡΡΠ·ΠΈΠΈ Π΄Π΅ΠΊΡΠΌΠ΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π° ΠΈΡΡ
ΠΎΠ΄Π½ΠΎ,Π½Π°13-ΠΈ, 45-Π΅, 910-Π΅, 1520-Π΅ ΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ.Π‘ΡΠ°ΡΡΠΎΠ²Π°Ρ Π΄ΠΎΠ·Π° Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π°ΠΏΡΠΈ ΡΠΈΠΌΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΠ°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π°ΡΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²ΠΎΡ0,12Π΄ΠΎ0,24 ΠΌΠΊΠ³/ΠΊΠ³/Ρ (ΡΡΠ΅Π΄Π½ΡΡ Π΄ΠΎΠ·Π° 0,160,01; ΡΡΠΌΠΌΠ°ΡΠ½ΠΎ 200 ΠΌΠΊΠ³/ΡΡΡ).ΠΠΎΡΠΈΡΡΠΎΠ²ΡΠΌ Π΄Π°Π½Π½ΡΠΌ ΠΠ Π‘ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Π°Ρ Π΄ΠΎΠ·Π° Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π° ΠΠ50ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 0,260,03 ΠΌΠΊΠ³/ΠΊΠ³/Ρ (ΡΡΠΌΠΌΠ°ΡΠ½ΠΎΠ·Π°ΡΡΡΠΊΠΈ 353,835,1 ΠΌΠΊΠ³)ΠΈΠ±ΡΠ»Π° Π΄ΠΎΡΡΠΈΠ³Π½ΡΡΠ°Π½Π°910- ΠΉ Π΄Π΅Π½Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π°.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅.ΠΠΎΡΡΠ΅ΠΊΡΠΈΡ ΡΠΈΠΌΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΠ°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈΠΏΡΠΈΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π° Π²ΡΠ·ΡΠ²Π°Π΅Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠΎΠ·Π½Π°Π½ΠΈΡ, ΡΠ½ΠΈΠΆΠ°Π΅Ρ ΡΠ°ΡΡΠΎΡΡ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΡΠ΅ΠΏΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΎΠΊΠ°, Π΄ΠΈΡΡΡΠ΅ΡΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Π»Π΅Π³ΠΊΠΈΡ
, Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡ
A randomized controlled study of the effectiveness of electrophysiological monitoring of dexmedetomidine in patients with brain damage of various origins [Π Π°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ»Π΅ΠΊΡΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° Π΄Π΅ΠΊΡΠΌΠ΅Π΄Π΅ΡΠΎΠΌΠΈΠ΄ΠΈΠ½Π° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ Π³Π΅Π½Π΅Π·Π°]
Background. At the same time, the main effect of the use of this drug is the elimination of the autonomic nervous system dysfunction and sympatholysis. It seems important to search for a method of indications and selection of a dose of dexmedetomidine in intensive care. Aims - to improve the clinical effectiveness of the electrophysiological navigation of the prolonged use of dexmedetomidine in patients with brain pathology of various origins. Methods. The study included 83 patients 20-50 days after the traumatic brain injury, anoxic damage; consequences of acute disorders of cerebral. 37 patients comprised the 1st intervention group with a clinical course of dexmedetomidine (male - 28; female - 9; average age 49.6 Β± 2.3 years) and 46 patients comprised the 2nd control group without pharmacological correction with dexmedetomidine (male - 23; female - 23, average age 51 Β± 2.5 years). Criteria for the inclusion of prolonged infusion of the drug dexmedetomidine (Orion Pharma, Finland) are based on heart rate variability (HRV) indicators characteristic of sympathetic hyperactivity, the target task of titration of doses of dexmedetomidine served as the parameters for achieving normal HRV indicators, the appearance of parasympathetic hyperactivity served as the basis for reducing the dosage of the drug or stopping it of application. HRV parameters were recorded before dexmetomedine infusion-initially, on 1-3; 4-5; 9-10; 15-20 days of drug administration. Results. The starting dose of dexmedetomidine with sympathetic hyperactivity in patients was 0.12 to 0.24 ΞΌg.kg-1.hr-1 (average dose 0.16 Β± 0.01; total 200 mg/day). According to digital data from HRV, the effective dose of dexmedetomidine ED50 was 0.26 Β± 0.03 ΞΌg.kg-1.hr-1 (total daily 353.8 Β± 35.1 ΞΌg) and was achieved on day 9-10 using dexmedetomidine. Conclusions. The protective role of dexmedetomidine with correction of sympathetic hyperactivity based on electrophysiological navigation according to the HRV is reliable in the following indicators: The improvement of consciousness; a significant decrease in the incidence of distress lung syndrome; septic shock; mortality. Β© 2020 Izdatel'stvo Meditsina. All rights reserved
Pulsar Striped Winds
According to magnetohydrodynamic (MHD) models, the rotational energy of a
rapidly spinning neutron star is carried away by a relativistic wind and
deposited at a large distance, in the nebula, downstream of the wind
termination shock. The energy transport in the outflow is mediated by Poynting
flux, but it is not clear how the energy stored in the fields is transferred
into the energized population of emitting particles. The most plausible
dissipation mechanisms are thought to be related to the "striped" structure of
the wind, in particular, to the existence of a current sheet, prone to
reconnection events. In this model the current sheet is a natural place for
internal dissipation and acceleration of particles responsible for pulsed,
high-energy emission. Moreover, reconnection is a promising scenario for
explaining annihilation of fields at the shock and conversion of their energy
into the kinetic energy of particles. The shock structure, however, is likely
to differ in the low-density plasmas, in which non-MHD effects intervene. In
this regime, the striped wind can dissipate its energy via an electromagnetic
precursor of the shock.Comment: invited review at the Workshop on Modelling Nebulae, June 14-17,
2016, Sant Cugat, Spain; submitted book chapte